689 results on '"Mancuso, James"'
Search Results
2. Quality and integrated service delivery: A cross-sectional study of the effects of malaria and antenatal service quality on malaria intervention use in sub-Saharan Africa
3. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
4. Smoking and multiple sclerosis risk in black people: A nested case-control study
5. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.
6. Unintended pregnancy among U.S. military active duty servicemembers: Estimates for 2018 and trends since 2005
7. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis
8. Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy.
9. Morbidity burden, seasonality and factors associated with the human respiratory syncytial virus, human parainfluenza virus, and human adenovirus infections in Kenya
10. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
11. Coverage of HIV Pre-Exposure Prophylaxis (PrEP) Within the Active Duty U.S. Military, 2023.
12. Tobacco and Nicotine Use Among Active Component U.S. Military Service Members: A Comparison of 2018 Estimates from the Health Related Behaviors Survey and the Periodic Health Assessment.
13. Suicidal Behaviors Among Active-Duty US Service Members: Data from the 2018 Health-Related Behaviors Survey
14. Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts
15. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
16. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials
17. Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
18. Perceived Health Status and Medical Conditions Among US Active-Duty Service Members.
19. A cross-sectional study of malaria endemicity and health system readiness to deliver services in Kenya, Namibia and Senegal
20. How 4 Companies Became One: Co-development Under an Outsourced Model With Focus on Phase 3 Analysis and Reporting Deliverables
21. Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
22. Abstract 4149: Anti-CTLA-4 generates memory T-cells with greater expansion and functionality than anti-PD-1
23. Data from A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention
24. Supplementary Data from A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention
25. Data from In Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors
26. Video S3 from In Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors
27. supplementary tables from In Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors
28. Supplementary figure 1-3 from In Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors
29. supplementary figure legends from In Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors
30. HEART FAILURE OUTCOMES CAPTURED BY ADVERSE EVENT REPORTING IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL
31. HYPOGLYCEMIA AND CV OUTCOMES IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL
32. Age-Adjusted Exact Trend Tests in the Event of Rare Occurrences
33. Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
34. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
35. Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease
36. COVID-19 Booster Vaccination in the U.S. Military, August 2021–January 2022
37. Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
38. gyrA and parC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Kenya
39. Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
40. Spatial and Spatio-Temporal Distribution of Human Respiratory Syncytial Virus, Human Parainfluenza Virus, and Human Adenoviruses Cases in Kenya 2007-2013
41. 859-P: Effects of Ertugliflozin on Uric Acid and Gout-Related Outcomes: Post Hoc Analyses from VERTIS CV
42. 481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV
43. 865-P: Long-Term Ertugliflozin Treatment and Incidence of Hypoglycemia: Analyses from VERTIS CV
44. Subarachnoid hemorrhage – Induced block of cerebrospinal fluid flow: Role of brain coagulation factor III (tissue factor)
45. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study
46. Advancing Health Equity in the US Military.
47. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
48. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV
49. Tuberculosis Screening and Control in the US Military in War and Peace
50. Impact of Targeted Testing for Latent Tuberculosis Infection Using Commercially Available Diagnostics
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.